This announcement is a separate document:
四川百利天恒药业股份有限公司自愿披露关于BL-B01D1(EGFR×HER3双抗ADC)项目研究成果在《柳叶刀·肿瘤学》(The Lancet Oncology)发布的公告
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily disclosed the research results of the BL-B01D1 (EGFR×HER3 bispecific antibody-drug conjugate) project in the announcement published in The Lancet Oncology.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.